|4-year-old girl in need of treatment for spinal muscular atrophy|
ROSEBURG, Ore. - Calypso, 4-year-old girl was born with a progressive neuromuscular condition, has a treatment available, but her mother says it's out of reach. 32 kids were invited to Calypso's birthday party but only three could make it; something as ...
KPIC News - Tue, 26 Jan 2016 17:52
|We are normal human beings, says Ben, who has spinal muscular atrophy|
Ben Morris has had spinal muscular atrophy all his life. But the 15-year-old, from Middleleaze, refuses to let it get the better of him. He talks to MARION SAUVEBOIS about his experiences of the condition and his ambitions for a future where there is ...
Swindon Advertiser - Tue, 19 Jan 2016 02:10
|Target Enrollment in Child Spinal Muscular Atrophy Study Earns Ionis $2M ...|
Ionis Pharmaceuticals announced it has completed its target enrollment of the Phase 3 CHERISH study, a trial designed to support marketing approval of the drug candidate nusinersen in children with spinal muscular atrophy (SMA). The achievement earned ...
SMA News Today - Thu, 14 Jan 2016 04:56
|Help Madi reach her fundraising goal|
I had just completed a lengthy conversion with Megan Ramirez, a-never-say-never optimist and mother of 10-year-old Madison "Madi'' Ramirez, who suffers from Spinal Muscular Atrophy. The dudes on the radio have no idea what tough is. Madi Ramirez .
Quad-Cities Online - Sun, 07 Feb 2016 19:22
|SMA fundraiser 'Rockin for a Cure' held at Liberty Auction|
The event raised money to help fight SMA (spinal muscular atrophy), a disease that robs people of physical strength by affecting motor nerve cells in the spinal cord. Concert goers enjoyed live music, food, a live auction, a gun raffle and even a 50/50 ...
WTVM - Sat, 06 Feb 2016 19:56
|Ionis Pharmaceuticals Completes Target Enrollment for Nusinersen Phase 3 Study ...|
The study is designed to support marketing approval of nusinersen in children with spinal muscular atrophy (SMA). "Achieving our target enrollment number in CHERISH brings us one step closer to a marketing application for children with SMA. We also ...
PR Newswire (press release) - Tue, 12 Jan 2016 04:00
|Ionis Pharma completes enrollment in late-stage nusinersen study, earns $2.15M ...|
Seeking Alpha - Tue, 12 Jan 2016 04:24
|CSU alum named new spokesperson for Muscular Dystrophy Association|
... Bill Clinton, all have hosted sessions with MDA ambassadors. “I've always dreamed of coming to New York, and this was the perfect opportunity to visit,” said Akmakjian, who was diagnosed with Spinal Muscular Atrophy Type 2 when he was 15 months old.
Colorado State University News (press release) - Thu, 04 Feb 2016 09:32
|Why Ionis Pharmaceuticals Inc Plunged 36% in January|
The CHERISh study is testing a compound called nusinersen as a new treatment option for patients with spinal muscular atrophy. Ionis presented at the JP Morgan Healthcare conference, where it announced that its 2015 net operating loss was going to come ...
Motley Fool - Sat, 06 Feb 2016 06:15